# MIRASOL (NCT04209855)

> A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04209855
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AbbVie
- Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
- Interventions: Mirvetuximab Soravtansine; Paclitaxel; Topotecan; Pegylated liposomal doxorubicin
- Enrollment: 453
- Primary outcome: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

## Commentary we found

- YouTube: 91
- Podcasts: 64
- X threads: 19
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=mirasol-nct04209855

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04209855", "email": "<work email>"}; the inbox owner confirms by the emailed link.